[go: up one dir, main page]

WO2000057918A3 - Novel formulations comprising lipid-regulating agents - Google Patents

Novel formulations comprising lipid-regulating agents Download PDF

Info

Publication number
WO2000057918A3
WO2000057918A3 PCT/US2000/007459 US0007459W WO0057918A3 WO 2000057918 A3 WO2000057918 A3 WO 2000057918A3 US 0007459 W US0007459 W US 0007459W WO 0057918 A3 WO0057918 A3 WO 0057918A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
regulating agents
novel formulations
concentrate
surfactants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/007459
Other languages
French (fr)
Other versions
WO2000057918A2 (en
Inventor
Rong Ron Liu
Qinghai Pan
Pawan Hansrani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to JP2000607667A priority Critical patent/JP2002540174A/en
Priority to AU40175/00A priority patent/AU4017500A/en
Priority to EP00919496A priority patent/EP1165141A2/en
Priority to MXPA01009839A priority patent/MXPA01009839A/en
Priority to HK02104718.1A priority patent/HK1044704A1/en
Priority to CA002367995A priority patent/CA2367995A1/en
Publication of WO2000057918A2 publication Critical patent/WO2000057918A2/en
Publication of WO2000057918A3 publication Critical patent/WO2000057918A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in a mixture of an oil and one or more surfactants to form a concentrate. This concentrate forms fine and stable emulsions upon gentle mixing with water or any aqueous solutions.
PCT/US2000/007459 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents Ceased WO2000057918A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000607667A JP2002540174A (en) 1999-03-31 2000-03-21 Novel formulation containing lipid regulator
AU40175/00A AU4017500A (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents
EP00919496A EP1165141A2 (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents
MXPA01009839A MXPA01009839A (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents.
HK02104718.1A HK1044704A1 (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents
CA002367995A CA2367995A1 (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28335699A 1999-03-31 1999-03-31
US09/283,356 1999-03-31

Publications (2)

Publication Number Publication Date
WO2000057918A2 WO2000057918A2 (en) 2000-10-05
WO2000057918A3 true WO2000057918A3 (en) 2001-01-18

Family

ID=23085656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007459 Ceased WO2000057918A2 (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents

Country Status (7)

Country Link
EP (1) EP1165141A2 (en)
JP (1) JP2002540174A (en)
AU (1) AU4017500A (en)
CA (1) CA2367995A1 (en)
HK (1) HK1044704A1 (en)
MX (1) MXPA01009839A (en)
WO (1) WO2000057918A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2819720B1 (en) 2001-01-22 2004-03-12 Fournier Lab Sa NEW FENOFIBRATE TABLETS
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
ES2255426B1 (en) 2004-10-19 2007-08-16 Gp Pharm, S.A. PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
BRPI0518426A2 (en) * 2004-12-06 2008-11-25 Reliant Pharmaceuticals Inc Pharmaceutical compositions comprising fenofibrates and solvent systems
JP5186159B2 (en) * 2006-08-31 2013-04-17 あすか製薬株式会社 Fenofibrate-containing composition
JP2013047282A (en) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd Fenofibrate-containing composition
EP2400840A4 (en) * 2009-02-24 2012-08-01 Madeira Therapeutics Liquid statin formulations
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102247598A (en) * 2011-06-13 2011-11-23 浙江爱生药业有限公司 Oil-soluble drug composition
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0336298A1 (en) * 1988-03-31 1989-10-11 E.R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
WO1995024893A1 (en) * 1994-03-16 1995-09-21 R.P. Scherer Limited Delivery systems for hydrophobic drugs
WO1999012528A1 (en) * 1997-09-11 1999-03-18 Smb Technology Self-emulsifiable semi-solid capsules with matrix system having prolonged action
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0336298A1 (en) * 1988-03-31 1989-10-11 E.R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
WO1995024893A1 (en) * 1994-03-16 1995-09-21 R.P. Scherer Limited Delivery systems for hydrophobic drugs
WO1999012528A1 (en) * 1997-09-11 1999-03-18 Smb Technology Self-emulsifiable semi-solid capsules with matrix system having prolonged action
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Also Published As

Publication number Publication date
HK1044704A1 (en) 2002-11-01
WO2000057918A2 (en) 2000-10-05
AU4017500A (en) 2000-10-16
EP1165141A2 (en) 2002-01-02
JP2002540174A (en) 2002-11-26
CA2367995A1 (en) 2000-10-05
MXPA01009839A (en) 2002-06-21

Similar Documents

Publication Publication Date Title
WO2000057918A3 (en) Novel formulations comprising lipid-regulating agents
HK1043936A1 (en) Novel formulations comprising lipid-regulating agents
EP0719137A4 (en) VISCOUS SURFACTANT COMPOSITIONS IN THE FORM OF EMULSIONS
NO994385D0 (en) Kroppsrengjöringsmiddel
WO2002045507A3 (en) Microemulsifiable agrochemical concentrate
MXPA02011487A (en) Novel surfactants and formulations.
DE60100032D1 (en) Cosmetic cleanser
CA2161428A1 (en) Skin Cleansing Formulations with Terpene Solvents and Corn Meal Scrubber
BR9600926A (en) Mixed micelles Aqueous process compositions for the preparation of mixed micelles and use
CA2304703A1 (en) Skin-compatible hand cleansers, particularly coarse hand cleansers
CA2368428A1 (en) Solid pot and pan detergent
DK1289502T3 (en) Microemulsion preconcentrate, microemulsion and use of a composition
ATE70403T1 (en) LIQUID PESTICIDE MIXED FORMULATIONS.
MX9804848A (en) Stable emulsions comprising a hydrophobic liquid ingredient.
AU554235B2 (en) Liquid cleansing compositions
WO2002096368A3 (en) Encapsulation of nanosuspensions in liposomes and microspheres
EP1066824A3 (en) Stimulative agent and stimulative perfume composition
BR0306796A (en) alkylglycol alkoxylate or alkyldiglycol alkoxylate, mixing and use of C 4-8-alkyl-glycols or -diglycol C 2-5-alkoxylates, washing, cleaning or humidifying or cosmetic agents, pharmaceutical or crop protection formulations, and, inks, color formulations, for spray applications, coating agent, adhesive, for leather, metal and textile treatment, flotation and foaming aids, and humectant
RU93045681A (en) CREAM MASK
CA2365265A1 (en) Stable aqueous compositions containing a silicon compound
DE59606882D1 (en) SHOWER COMPOSITION WITH GINKGO-BILOBA DRY EXTRACT
EP0828814A4 (en) Aqueous personal cleansing composition with a dispersed oil phase comprising two specifically defined oil components
ES2169119T3 (en) IBUPROFEN-BASED LIQUID PHARMACEUTICAL COMPOSITIONS.
EP0795003A4 (en) Detergent composition comprising clay and polysaccharide gum stabilizing agents
WO2001055285A3 (en) Rinsing and cleaning agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367995

Country of ref document: CA

Ref country code: CA

Ref document number: 2367995

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 607667

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009839

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000919496

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919496

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000919496

Country of ref document: EP